Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Radiation Oncology
Should size of non-mass enhancement on breast MRI be incorporated in breast cancer staging?
Related Questions
Is it reasonable to offer APBI in an obese patients with large breasts and N1mi disease?
In a clinically node negative early stage breast cancer patient who underwent neoadjuvant systemic therapy, would surgical finding of fibrosis suspicious for treatment effect in sentinel nodes impact your RT decision?
How would you approach post-operative radiation in a patient with ER/PR negative Her2 positive, T1c N0 breast cancer originating in the ectopic mammary tissue close to the axilla, treated wide excision followed by APT regimen (weekly paclitaxel plus trastuzumab with trastuzumab for one year)?
What are your thoughts on the relevance of sentinel lymph node biopsy before the onset of neoadjuvant chemotherapy for HER2+ or triple negative cT2+N0M0 breast cancer patients?
Would you omit post-lumpectomy radiotherapy for high clinical risk, but low molecular risk DCIS?
Is Behcet's disease a contraindication to breast conserving therapy?
Is there any situation where hypofractionation of post-mastectomy radiation (CW and regional nodes) is absolutely contraindicated?
How do you approach capsular contracture after breast radiotherapy?
Do you offer APBI for patients with invasive disease if there is high grade DCIS present in the lumpectomy specimen?
What is your preferred PMRT dose/fractionation for patients with implant reconstruction?
